v3.26.3
Financial Assets and Financial Liabilities - Schedule of Other Financial Liabilities (Details) - USD ($)
Jun. 30, 2026
Jun. 30, 2025
Schedule of Other Financial Liabilities [Line Items]    
Other financial liabilities, Current $ 6,860,850 $ 3,421,337
Other financial liabilities, Non- current 18,912,929 28,676,987
Other financial liabilities, Total 25,773,779 32,098,324
Diaprost Contingent Consideration [Member]    
Schedule of Other Financial Liabilities [Line Items]    
Other financial liabilities, Current 1,979,902 1,328,087
Other financial liabilities, Non- current 6,916,482 8,841,829
Other financial liabilities, Total 8,896,384 10,169,916
NanoMab Contingent Consideration [Member]    
Schedule of Other Financial Liabilities [Line Items]    
Other financial liabilities, Current [1] 4,502,764 1,832,833
Other financial liabilities, Non- current [1] 1,050,443 4,899,858
Other financial liabilities, Total [1] 5,553,207 6,732,691
NeoIndicate Contingent Consideration [Member]    
Schedule of Other Financial Liabilities [Line Items]    
Other financial liabilities, Current [2]
Other financial liabilities, Non- current [2] 1,870,454
Other financial liabilities, Total [2] 1,870,454
Pivalate Contingent Consideration [Member]    
Schedule of Other Financial Liabilities [Line Items]    
Other financial liabilities, Current 378,184 225,245
Other financial liabilities, Non- current 1,646,950 1,933,981
Other financial liabilities, Total 2,025,134 2,159,226
Pharma15 Deferred Consideration [Member]    
Schedule of Other Financial Liabilities [Line Items]    
Other financial liabilities, Current [3]
Other financial liabilities, Non- current [3]
Other financial liabilities, Total [3]
Pharma15 Contingent Consideration [Member]    
Schedule of Other Financial Liabilities [Line Items]    
Other financial liabilities, Current
Other financial liabilities, Non- current 1,134,164
Other financial liabilities, Total 1,134,164
TRIMT Contingent Consideration [Member]    
Schedule of Other Financial Liabilities [Line Items]    
Other financial liabilities, Current
Other financial liabilities, Non- current 7,758,256 8,423,667
Other financial liabilities, Total 7,758,256 8,423,667
UCLA Contingent Consideration [Member]    
Schedule of Other Financial Liabilities [Line Items]    
Other financial liabilities, Current
Other financial liabilities, Non- current
Other financial liabilities, Total
MD Anderson Contingent Consideration [Member]    
Schedule of Other Financial Liabilities [Line Items]    
Other financial liabilities, Current 35,172
Other financial liabilities, Non- current 1,540,798 1,573,034
Other financial liabilities, Total 1,540,798 1,608,206
Advanced Payment Liability [Member]    
Schedule of Other Financial Liabilities [Line Items]    
Other financial liabilities, Current
Other financial liabilities, Non- current
Other financial liabilities, Total
[1] Payment to be made in the form of ordinary shares in the company, based on the price of the 7-day volume weighted average price (VWAP) prior to the announcement of the milestone on the ASX.
[2] The NeoIndicate asset was handed back to the university during the financial year, resulting in the unwinding of contingent consideration for its milestone payments.
[3] The Pharma15 asset was fully impaired during the year and as a result the likelihood of milestones being met for the progression of the asset has been also reduced to nil.